SCHEMBL4581560

SCHEMBL4581560

CC(=O)Nc1ccccc1S(=O)(=O)N(C)C(C)c1nc2ccccc2c(=O)n1-c1ccc(C)cc1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TDO2 P48775 1/20 0.41
IDO2 Q6ZQW0 1/20 0.41
HTR7 P34969 3/20 0.40
CXCR3 P49682 2/20 0.39
KDR P35968 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 3/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.37
PDE10A Q9Y233 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
HPD P32754 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451272 0.88 ALDH1A1 (0.48) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL450965 0.87 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL451938 0.85 ALDH1A1 (0.54) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL453890 0.85 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL451936 0.84 ALDH1A1 (0.53) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL4581565 0.84 ALDH1A1 (0.48) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL452764 0.83 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL454036 0.83 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL449870 0.83 ALDH1A1 (0.50) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2
SCHEMBL450059 0.82 ALDH1A1 (0.51) ALDH1A1MAPTSMN1; SMN2KDM4ETDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885MAPT 4075/4885SMN1; SMN2 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.